World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 7 December 2015
Main ID:  NCT01880619
Date of registration: 13/06/2013
Prospective Registration: No
Primary sponsor: Mansoura University
Public title: Comparison of Tamsulosin and Solifenacin in Treatment of Ureteral Stent Symptoms
Scientific title: A Randomized Clinical Trial Comparing Alpha Blacker (Tamsulosin) and Anticholinergic (Solifenacin) in Treatment of Ureteral Stent Related Symptoms
Date of first enrolment: January 2013
Target sample size: 131
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT01880619
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment  
Phase:  Phase 4
Countries of recruitment
Egypt
Contacts
Name:     Ahmed R EL-Nahas, A. Professor
Address: 
Telephone:
Email:
Affiliation:  Urology and Nephrology Center, Mansoura University
Key inclusion & exclusion criteria

Inclusion Criteria:

Patient who will undergo unilateral ureteral stent fixation:

1. To relieve upper urinary tract obstruction caused by ureteric calculi

2. After ureteroscopic lithotripsy for ureteral calculi.

Exclusion Criteria:

1. Patients who had LUTS before stent fixation.

2. Ureteral stent fixation after open or laparoscopic surgery.

3. Bilateral ureteral stents.

4. Patients who developed complications related to the primary endoscopic procedure

5. Patients who developed stent related complications such as hematuria, acute
pyelonephritis or stent displacement



Age minimum: 20 Years
Age maximum: 50 Years
Gender: Both
Health Condition(s) or Problem(s) studied
Relieve of Ureteral Stent Symptoms
Intervention(s)
Drug: Control
Drug: Solifenacin
Drug: Tamsulosin
Primary Outcome(s)
The Efficacy of tamsulosin and solifenacin in relieving ureteral stent symptoms will be evaluated by comparing the scores of ureteral stent symptoms questionnaire in the studied groups [Time Frame: 1 year]
Secondary Outcome(s)
Secondary ID(s)
Treatment of USS
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history